EntryPoint Capital LLC Increases Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

EntryPoint Capital LLC boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 67.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,503 shares of the company’s stock after purchasing an additional 605 shares during the period. EntryPoint Capital LLC’s holdings in Medpace were worth $499,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MEDP. Pallas Capital Advisors LLC increased its position in shares of Medpace by 179.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after buying an additional 2,101 shares in the last quarter. Barclays PLC grew its stake in Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after acquiring an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC increased its holdings in Medpace by 20.5% during the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock valued at $1,738,000 after acquiring an additional 844 shares in the last quarter. Janus Henderson Group PLC raised its position in Medpace by 10.0% during the third quarter. Janus Henderson Group PLC now owns 44,118 shares of the company’s stock worth $14,722,000 after acquiring an additional 4,023 shares during the last quarter. Finally, SYM FINANCIAL Corp purchased a new stake in shares of Medpace in the fourth quarter valued at about $320,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Trading Down 1.8 %

Shares of NASDAQ:MEDP opened at $324.51 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The stock’s 50-day moving average price is $337.16 and its two-hundred day moving average price is $339.57. The firm has a market cap of $9.89 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MEDP has been the subject of a number of recent research reports. Leerink Partners initiated coverage on shares of Medpace in a research note on Monday. They set a “market perform” rating and a $330.00 price objective for the company. Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Finally, Leerink Partnrs upgraded Medpace to a “hold” rating in a research report on Monday. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $376.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.